Matt D. Galsky, MD, on Bladder Cancer: Neoadjuvant Therapy With Gemcitabine, Cisplatin, and Nivolumab

June 22, 2021 By The ASCO Post Staff

Matt D. Galsky, MD, of the Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai, discusses results from a phase II trial designed to test gemcitabine and cisplatin plus nivolumab as neoadjuvant therapy in patients with muscle-invasive bladder cancer and to better predict benefit in those who opted out of cystectomy (Abstract 4503).

Related Content